CJ 040,714

Drug Profile

CJ 040,714

Alternative Names: CJ-040714

Latest Information Update: 02 Mar 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Amides; Antiulcers; Benzimidazoles; Piperidines; Pyrans; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastro-oesophageal reflux

Most Recent Events

  • 01 Mar 2016 Phase-II development is ongoing in United Kingdom (EudraCT 2005-004155-35)
  • 01 Dec 2005 Phase-II clinical trials in Gastro-oesophageal reflux in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top